{
    "id": 50909,
    "name": "MALT lymphoma",
    "source": "DOID",
    "definition": "A marginal zone B-cell lymphoma that has_material_basis_in mucosal tissue involved in antibody production. [url:http\\://www.cancer.gov/dictionary?CdrID=45774, url:http\\://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/malt]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050909",
    "evidence": [
        {
            "id": 8440,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDC-0917 treatment induced rapid decrease of Birc2 (cIAP-1) level, and resulted in sustained complete response in a patient with mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach, who remained disease-free for over 2 years after discontinuing treatment (PMID: 27076626).",
            "molecularProfile": {
                "id": 26248,
                "profileName": "BIRC2 positive"
            },
            "therapy": {
                "id": 3639,
                "therapyName": "GDC-0917",
                "synonyms": null
            },
            "indication": {
                "id": 50909,
                "name": "MALT lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6658,
                    "pubMedId": 27076626,
                    "title": "A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076626"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10499,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Chlorambucil and Rituxan (Rituximab) combination treatment resulted in improved event-free survival (HR=0.54) but not longer overall survival in patients with mucosa-associated lymphoid tissue lymphoma (PMID: 28355112).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5544,
                "therapyName": "Chlorambucil + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50909,
                "name": "MALT lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8570,
                    "pubMedId": 28355112,
                    "title": "Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28355112"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19105,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYD88 mutations aid in the diagnosis of MALT lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 1917,
                "profileName": "MYD88 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50909,
                "name": "MALT lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02564744",
            "title": "Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6931,
                    "therapyName": "IMGN529 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03147885",
            "title": "Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696784",
            "title": "Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 7976,
                    "therapyName": "Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                }
            ]
        }
    ]
}